Bayer, NeuroCycle partner to advance pet allergy treatmentsSeptember 18, 2018Bayer Animal Health and NeuroCycle Therapeutics Inc. have signed a global license agreement to advance allergy treatment options for companion animals. As part of the license agreement, Bayer will develop and commercialize novel compounds based on NeuroCycle's intellectual property. "[This] agreement underlines our strategy to combine the know-how from creative startup companies like NeuroCycle with opportunities derived from Bayer's research," said Douglas Hutchens, DVM, PhD, Bayer Animal Health's head of drug discovery, external innovation and chief veterinary officer. "It is a major milestone on our way to complementing our portfolio with novel treatment options against allergic diseases for the companion animal sector." The companies' goal is to maximize the humanitarian impact of their innovative technologies, according to Jed Hubbs, PhD, MS, CEO of NeuroCycle Therapeutics.
Education Center - SponsoredWhy Some Dogs Keep Seizing: Understanding and Managing Refractory Epilepsyby • PRN PharmacalThe severe impact of drug-resistant epilepsy highlights the importance of aiming for complete seizure control in all dogs experiencing seizures. It's crucial to enhance our understanding of the reasons behind drug resistance and how they relate to various causes, progression of the disease, and affected breeds.
